Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

ISTODAX: Cutaneous T-cell lymphoma after prior therapy

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).

Broader topic: Cutaneous T-Cell Lymphomas

Source population
Not part of this definition
Disease extent
Not part of this definition
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
    prior therapy
    1. class
      who have received at least one prior systemic therapy ( 1 )
      status
      required
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for ISTODAX (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    ISTODAX is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy ( 1 ).

    Study evidence for this setting

    0 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    No linked study matches these filters. This is a source-coverage gap, not evidence that there are no treatment options.

    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice